PACH-72: PHYSICO-CHEMICAL EVALUATION OF THE PERSEITOL OBTAINED FROM PERU AND CUBA AVOCADO (Persea americana)

J Pharm Pharmacogn Res 3(suppl. 1): S165, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Poster

PACH-72: PHYSICO-CHEMICAL EVALUATION OF THE PERSEITOL OBTAINED FROM PERU AND CUBA AVOCADO (Persea americana)

García CM, Martínez V, González ML, Martínez L, Rivera MM, Sánchez P, Rosas LO.

Center for Pharmaceutical Research and Drug Development (CIDEM). Ave. 26 # 1605 e/ Boyeros y Puentes Grandes, Havana, Cuba. E-mail: caridadgp@infomed.sld.cu, caridad.garcia@cidem.sld.cu

 

Introductions: This study summarizes the main findings of the preliminary characterization of plant material obtained from the bark of avocados from Peru and Cuba (Persea americana) used to obtain perseitol, an active ingredient, with a high potential as raw material in the further development of pharmaceutical formulations. Material and Methods: Avocado plants, purple variety, used in the study were planted in the Experimental Station of Medicinal Plants Dr. Juan Tomas Roig, Cuba. To study the physico-chemical parameters were used IR spectroscopy and high performance liquid chromatography (HPLC), as well as other tests described in the Branch Standard of the Ministry of Public Health (NRSP 309). Results: The results obtained for each sample tested, showed no significant differences between the perseitol obtained from Cuba in relation to Peru. Conclusions: These preliminary results demonstrated that perseitol has quality enough for its use in pharmaceutical formulations.

 

Citation Format: García CM, Martínez V, González ML, Martínez L, Rivera MM, Sánchez P, Rosas LO (2015) Physico-chemical evaluation of the perseitol obtained from Peru and Cuba avocado (Persea americana). [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S165. Abstract nr PACH-72.